Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology

Autor: Bloudek B, Wirtz HS, Hepp Z, Timmons J, Bloudek L, McKay C, Galsky MD

Publikováno v: Clinical Epidemiology, Vol Volume 14, Pp 1375-1386 (2022)

Brian Bloudek,1 Heidi S Wirtz,2 Zsolt Hepp,2 Jack Timmons,1 Lisa Bloudek,1 Caroline McKay,3 Matthew D Galsky4 1Curta Inc., Seattle, WA, USA; 2Seagen Inc., Bothell, WA, USA; 3Astellas Pharma Global Development, Inc., Northbrook, IL, USA; 4Tisch Cancer

Externí odkaz: https://doaj.org/article/d72735e9e396462e9a5a6a49363c5649

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Autor: Grivas, P, Khaki, AR, Wise-Draper, TM, French, B, Hennessy, C, Hsu, C-Y, Shyr, Y, Li, X, Choueiri, TK, Painter, CA, Peters, S, Rini, BI, Thompson, MA, Mishra, S, Rivera, DR, Acoba, JD, Abidi, MZ, Bakouny, Z, Bashir, B, Bekaii-Saab, T, Berg, S, Bernicker, EH, Bilen, MA, Bindal, P, Bishnoi, R, Bouganim, N, Bowles, DW, Cabal, A, Caimi, PF, Chism, DD, Crowell, J, Curran, C, Desai, A, Dixon, B, Doroshow, DB, Durbin, EB, Elkrief, A, Farmakiotis, D, Fazio, A, Fecher, LA, Flora, DB, Friese, CR, Fu, J, Gadgeel, SM, Galsky, MD, Gill, DM, Glover, MJ, Goyal, S, Grover, P, Gulati, S, Gupta, S, Halabi, S, Halfdanarson, TR, Halmos, B, Hausrath, DJ, Hawley, JE, Hsu, E, Huynh-Le, M, Hwang, C, Jani, C, Jayaraj, A, Johnson, DB, Kasi, A, Khan, H, Koshkin, VS, Kuderer, NM, Kwon, DH, Lammers, PE, Li, A, Loaiza-Bonilla, A, Low, CA, Lustberg, MB, Lyman, GH, McKay, RR, McNair, C, Menon, H, Mesa, RA, Mico, V, Mundt, D, Nagaraj, G, Nakasone, ES, Nakayama, J, Nizam, A, Nock, NL, Park, C, Patel, JM, Patel, KG, Peddi, P, Pennell, NA, Piper-Vallillo, AJ, Puc, M, Ravindranathan, D, Reeves, ME, Reuben, DY, Rosenstein, L, Rosovsky, RP, Rubinstein, SM, Salazar, M, Schmidt, AL, Schwartz, GK

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology, vol 32, iss 6

BackgroundPatients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::32464797f1049465c364360d3ca626d5
https://escholarship.org/uc/item/49m429m0

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

Autor: Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G

Publikováno v: BJU international. 113(5b)

Objective To study the impact of the prognostic factors liver metastasis (LM), anaemia (haemoglobin [Hb] = 1 and time from previous chemotherapy (TFPC) on the activity of second-line therapy for advanced urothelial carcinoma (UC). Patients and Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::457ed714250f5801f67782c6cc5700ee
https://pubmed.ncbi.nlm.nih.gov/24219029

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Emerging personalized approaches for the management of advanced urothelial carcinoma.

Autor: Tsao CK, Gartrell BA, Oh WK, Galsky MD, Tsao, Che-Kai, Gartrell, Benjamin A, Oh, William K, Galsky, Matthew D

Publikováno v: Expert Review of Anticancer Therapy; Dec2012, Vol. 12 Issue 12, p1537-1543, 7p